129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

Background: Canagliflozin reduces the incidence of kidney and cardiovascular events in people with type 2 diabetes and chronic kidney disease (CKD). We assessed the effects of canagliflozin according to age and sex in a randomized, placebo-controlled trial. Methods: The CREDENCE study randomized par...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2021-06, Vol.70 (Supplement_1)
Hauptverfasser: YI, TAE WON, SMYTH, BRENDAN, KANG, AMY, CARDOZA, KATHRYN, TANNA, GIAN LUCA DI, ARNOTT, CLARE, POLLOCK, CAROL A., AGARWAL, RAJIV, BAKRIS, GEORGE, CANNON, CHRISTOPHER P., DE ZEEUW, DICK, HEERSPINK, HIDDO L., LEVIN, ADEERA, NEAL, BRUCE, WHEELER, DAVID C., ZHANG, HONG, ZINMAN, BERNARD, MAHAFFEY, KENNETH W., PERKOVIC, VLADO, JARDINE, MEG J.
Format: Artikel
Sprache:eng
Schlagworte:
Adverse events
Age
Antidiabetics
Cardiovascular diseases
Creatinine
Diabetes
Diabetes mellitus (non-insulin dependent)
Hypoglycemia
Kidney diseases
Placebos
Regression analysis
Renal failure
Sex
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Canagliflozin reduces the incidence of kidney and cardiovascular events in people with type 2 diabetes and chronic kidney disease (CKD). We assessed the effects of canagliflozin according to age and sex in a randomized, placebo-controlled trial. Methods: The CREDENCE study randomized participants with type 2 diabetes and albuminuric CKD. The effects of canagliflozin on the primary outcome (a composite of kidney failure, a doubling of the serum creatinine level, or death from kidney or cardiovascular causes), and secondary outcomes were evaluated by age at baseline (
ISSN:0012-1797
1939-327X
DOI:10.2337/db21-129-LB